Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT06962800 · View on ClinicalTrials.gov ↗
Study Summary
In this study, researchers will learn more about the use of felzartamab in participants with primary membranous nephropathy, also known as PMN. In people with PMN, autoantibodies build up in the glomeruli of the kidney. Antibodies are proteins that help the body fight off infection. An autoantibody is a type of antibody that mistakenly targets and attacks the body's own tissues. Glomeruli are the filters of the kidney that remove waste and extra fluid from the body. In PMN, the build-up of autoantibodies in the glomeruli causes damage to the kidneys. Kidney damage can lead to too much protein and blood leaking into the urine. High levels of protein in the urine, called proteinuria, are common in people with PMN. Symptoms of PMN can include swelling in the legs and body, tiredness, and high blood pressure. If left untreated, PMN can eventually lead to kidney failure. In this study, researchers will learn more about how a study drug called felzartamab affects people with PMN. Felzartamab is a monoclonal antibody, which means it is an antibody made in a laboratory. Felzartamab can target immune cells that produce autoantibodies, helping to lower their buildup in the kidneys. The main goal of this study is to compare how felzartamab works compared to a drug called tacrolimus. Tacrolimus is another drug given to people with PMN and kidney disease. The main question that researchers want to answer is: * How many participants achieve a complete response after 104 weeks of treatment? * A complete response means that their urine protein levels decrease to a low level and their kidney function remains stable. Researchers will also learn about: * How long it takes before the participants' disease gets worse * How long the participants' urine protein levels stay low * How many participants develop antibodies against felzartamab in the blood? * How many participants achieve a complete response after 76 weeks of treatment * How many participants have medical problems during
Conditions Studied
Interventions
- DRUG Tacrolimus
- DRUG Felzartamab
- DRUG Standard of Care IST
Study Locations (20)
Other
- Organización Médica de Investigación — Buenos Aires
- CINME S.A. - Centro de Investigaciones Metabólicas — Buenos Aires
- Hospital Italiano de Buenos Aires — Buenos Aires
- Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada — Buenos Aires
- Clínica Privada Vélez Sarsfield — Córdoba
California
- The Nephrology Group, Inc. - Fresno — Fresno
- Academic Medical Research Institute — Los Angeles
- UCSF Medical Center — San Francisco
New South Wales
- Concord Hospital — Concord
- St George Hospital — Kogarah
- Westmead Hospital — Westmead
Michigan
- Henry Ford Hospital- A-Basement Research Pharmacy — Detroit
- Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDS — Pontiac
Texas
- Nephrotex Research Group — Dallas
- University of Texas Medical Branch — League City
Alabama
- Apogee Clinical Research, LLC — Huntsville
New York
- James J Peters Veterans Administration Medical Center - NAVREF - PPDS — The Bronx
North Carolina
- ECU Physicians Nephrology and Hypertension — Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-05-22 |
| Est. Completion | 2029-03-29 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06962800
The ClinicalTrials.gov registry entry for NCT06962800 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 74 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Primary Membranous Nephropathy appearing as the primary indexed condition, and to 3 interventions — of which Tacrolimus is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06962800 reports 20 study locations spanning 10 distinct geographic areas — top geographies include Other, California, New South Wales. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06962800 about?
NCT06962800 is a clinical study titled "A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)". In this study, researchers will learn more about the use of felzartamab in participants with primary membranous nephropathy, also known as PMN. In people with PMN, autoantibodies build up in the glomeruli of the kidney. Antibodies are proteins that help the body fight off infection. An autoantibody ...
What is the current status of trial NCT06962800?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2025-05-22. Estimated completion is 2029-03-29.
What conditions does trial NCT06962800 study?
This clinical trial studies the following conditions: Primary Membranous Nephropathy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06962800?
The interventions under investigation include: Tacrolimus (DRUG), Felzartamab (DRUG), Standard of Care IST (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06962800?
This trial is sponsored by Biogen, which has 74 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06962800 being conducted?
This trial has 20 study locations across Alabama, California, Michigan, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.